Tag: PSA
PCa17: Interactive, compact meeting opens in Vienna
Challenges in diagnosis, staging and patient selection were among the issues taken up in the first plenary session of the EAU Update on Prostate Cancer (PCa17) opened in Vienna today. With more than 300 participants including faculty and exhibitors,...
Tumour characteristics and patient profile: Crucial issues in PCa treatment
Despite advances in diagnostic tools and imaging technologies, prostate cancer (PCa) management remains a challenge to many experts due to extensive variability in tumour characteristics and individual patient profiles which complicate the delivery of an optimal treatment plan. “There...
Where do we stand with predictive biomarkers in mCRPC?
Treatment options for men with metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, cabazitaxel and radium-2231-6. With evidence that both abiraterone acetate and enzalutamide are effective agents when administered...